Real-world data published in Heart Rhythm reveals that 24–48-hour monitoring can miss actionable arrhythmias, emphasizing the value of iRhythm’s Zio long-term continuous monitoring (LTCM). Additional studies presented at AHA 2025 show high compliance and data quality with at-home self-application of Zio devices, as well as earlier arrhythmia detection in at-risk populations. These findings challenge the preference for short-duration monitoring and highlight the benefits of long-term continuous monitoring. iRhythm continues to advance proactive cardiac care to detect arrhythmias before serious outcomes occur, with a focus on improving patient outcomes through data-driven solutions.

Read more at GlobeNewswire: iRhythm Technologies Announces Publication of Large-Scale